英文名稱(chēng) | VX-702 |
---|---|
中文名稱(chēng) | 2-(2,4-二氟苯基)-6-(1-(2,6-二氟苯基)脲基)煙酰胺 |
CAS號(hào) | 745833-23-2 |
分子式 | C19H12F4N4O2 |
分子量 | 404.32 |
MDL | MFCD11616590 |
外觀(guān) | White to off-white powder |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無(wú)牌價(jià)信息,您可以發(fā)送詢(xún)價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱(chēng) | VX-702 |
---|---|
中文名稱(chēng) | 2-(2,4-二氟苯基)-6-(1-(2,6-二氟苯基)脲基)煙酰胺 |
CAS號(hào) | 745833-23-2 |
分子式 | C19H12F4N4O2 |
分子量 | 404.32 |
MDL | MFCD11616590 |
外觀(guān) | White to off-white powder |
VX-702 is recognized as a highly selective inhibitor of p38α MAPK, with a 14-fold greater potency against p38α compared to p38β. This second-generation inhibitor is known for its high specificity and oral activity, making it a valuable tool in the research and potential treatment of inflammatory diseases, particularly rheumatoid arthritis.
Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation.
PMID: 15583748 DOI: 10.1160/TH04-03-0187
PMID: 26289811 PMCID: PMC4560789 DOI: 10.1038/ncomms9039